Glassia bottle Shire and Kamada announced that the Food and Drug Administration (FDA) has approved Glassia (alpha-1 proteinase inhibitor [human]) as the first treatment for adults with emphysema due ...
Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announces a significantly improved infusion rate for Glassia (Alpha1-Proteinase Inhibitor -Human); this ...
Shire’s emphysema therapy Glassia has received FDA approval for an expanded label, marking the first time that patients can self-infuse at home. Glassia, an alpha-1 proteinase inhibitor, is licensed ...
Kamada Ltd. (NASDAQ:KMDA) and U.S. distributor Shire plc (SHPG) announce that the FDA has approved an expanded label for GLASSIA [Alpha-1 Proteinase Inhibitor (Human)] allowing for self-infusion at ...
REHOVOT, Israel, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that, following recent discussions with Takeda ...
NESS ZIONA, Israel, Sep 29, 2014 (BUSINESS WIRE) -- Kamada Ltd. KMDA, +0.45% (tase:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the second ...
REHOVOT, Israel, April 07, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced an amendment to the GLASSIA® [Alpha ...
(RTTNews) - Takeda Canada Inc., the Canadian arm of Japan's Takeda Pharmaceutical Co. Ltd. (TAK) on Wednesday entered into a contract with Canadian Blood Services (CBS) for GLASSIA (alpha-1 proteinase ...
Kamada Ltd. (KMDA) (KMDA.TA), a plasma-derived protein therapeutics company focused on orphan indications, announced today the second extension to supply Glassia® to Baxter in its strategic agreement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results